Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer
Expanded Role Strengthens Top Tier of Company’s Executive Leadership Team SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Keith Kennedy , the company’s current chief financial
View HTML
Toggle Summary Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis
Genomic Test is Veracyte’s First Commercial Product to Emerge Since Entering into Strategic Collaboration with Johnson & Johnson Innovation SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 26, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it
View HTML
Toggle Summary Veracyte Named a San Francisco Bay Area “Top Workplace” For Sixth Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 24, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the company has been awarded a Top Workplaces 2019 honor by the Bay Area News Group for the sixth consecutive year.
View HTML
Toggle Summary Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
- Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that a review article in Cancer Cytopathology , a journal of the American Cancer
View HTML
Toggle Summary Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma ® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce
View HTML
Toggle Summary Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis
New Findings Presented at 2019 ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the potential for its Afirma ® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients
View HTML
Toggle Summary Veracyte Announces Participation in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at two upcoming investor conferences: The William Blair 39 th Annual Growth Stock Conference in Chicago
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data demonstrating the Afirma® Xpression Atlas test’s ability to detect gene alterations that may be targeted by new treatments for medullary thyroid cancer – a rare, but aggressive
View HTML
Toggle Summary Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced new data demonstrating that its next-generation Percepta ® Genomic Sequencing Classifier (GSC) provides expanded lung cancer risk information that can
View HTML